Toggle light / dark theme

Worldwide, 800,000 people die annually due to suicide (1 every 40 seconds) — There are more than twice as many suicides as homicides — Suicide is now the 10th leading cause of death in the US, and the 2nd leading cause of death among individuals between ages of 10 and 34 — Dr. Christine Moutier, M.D., Chief Medical Officer, American Foundation for Suicide Prevention, joins me on ideaXme to discuss her organization’s work in suicide prevention science and impacting these disturbing trends — #Ideaxme #Suicide #Depression #MentalHealth #Psychiatry #Anxiety #Stress #Trauma #Coronavirus #Burnout #WellBeing #Resilience #Health #Wellness #Longevity #Aging #IraPastor #Bioquark #Regenerage National Institute of Mental Health National Academy of Medicine.


Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews Dr. Christine Moutier, MD, Chief Medical Officer, at the American Foundation for Suicide Prevention (AFSP).

Ira Pastor comments:

Actually, the predominant language of the website is English, but even me being bilingual, I felt more comfortable delivering the narrative in my native language.

In the video, I give a thorough overview of the content and organization of my website Transhumanplus.com. It has a huge amount of information, growing constantly, on the transhumanist movement, emerging technologies in general, and very specially, on the longevity, rejuvenation and life extension field.

The idea is to provide a 20 minute guide to visitors, so you can have a good understanding and take the most out of it when surfing the web.

If you enjoy the video or are interested in these matters, I invite you to contact me through any of the following social media channels:

Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.

Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.

A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.

Middle-aged mice that had the naturally-occurring metabolite alpha-ketaglutarate (AKG) added to their chow had a better “old age.” They were healthier as they aged and experienced a dramatically shorter time of disease and disability before they died, a first for research involving mammals. Results from the double-blinded study, published in Cell Metabolism, were based on clinically-relevant markers of healthspan.

Previous studies show that blood plasma levels of AKG can drop up to 10-fold as we age. Fasting and exercise, already shown to promote longevity, increase the production of AKG is not found in the normal diet, making supplementation the only feasible way to restore its levels.

“The standard for efficacy in research on aging is whether interventions actually improve healthspan. We’ve reached that mark here with a compound that is naturally produced by the body and is generally shown to be safe,” said Buck professor and senior author Gordon Lithgow, Ph.D… Noting that some of the mice did experience moderate lifespan extension (the average was around 12%), measures of healthspan increased more than 40 percent. Lithgow says the goal is always to compress the time of disease and frailty. “The nightmare scenario has always been life extension with no reduction in disability. In this study, the treated middle-aged mice got healthier over time. Even the mice that died early saw improvements in their health, which was really surprising and encouraging.”

Excerpts of talks and interviews on biological radical life extension given by some of the world top longevity scientists.
The compendium includes thoughts, predictions and claims made by the following longevity leaders (listed in alphabetical order):
Aubrey de Grey, PhD: https://en.wikipedia.org/wiki/Aubrey_de_Grey
David Sinclair, PhD: https://en.wikipedia.org/wiki/David_Andrew_Sinclair
George Church, PhD: https://en.wikipedia.org/wiki/George_Church_(geneticist)
Juan Carlos Izpisúa Belmonte, PhD: https://en.wikipedia.org/wiki/Juan_Carlos_Izpisua_Belmonte
María Blasco Marhuenda, PhD: https://en.wikipedia.org/wiki/Mar%C3%ADa_Blasco_Marhuenda

I added embedded subtitles in English when scientists speak in Spanish.
For subtitles in Spanish when scientists speak in English, just choose the option in Youtube to add the subtitles in Spanish I created.

These are some of my social media channels, you’re invited to keep in touch through any of them:
LinkedIn: https://www.linkedin.com/in/andresgrases/
Facebook: https://www.facebook.com/andres.grases
Instagram: https://www.instagram.com/andgrabri/
Youtube: https://www.youtube.com/andresgrases

This is my own website which includes a digital library with more than 26.000 links and growing, organized in 19 main categories and many other sub-categories: https://transhumanplus.com/

A striking new study has found young cancer survivors show high expression of a gene known to be an effective marker of aging. The researchers suggest this genetic biomarker could be used to identify cancer survivors most at risk of later-life frailty due to their treatment.

As we age, concentrations of a gene called p16INK4a gradually increase in our cells, making it a potentially useful molecular marker for aging. One of the gene’s roles is to slow cell division and reduce the proliferation of stem cells.

In a new study researchers set out to investigate p16INK4a levels in pediatric and young adult cancer survivors. The hypothesis was that increased p16INK4a levels could be an effective sign of frailty among young cancer survivors.

This is an excerpt of a conversation between Dr. Daniel Stickler and Brian Rose.
Dr. Stickler is the Medical Director for the Neurohacker Collective, a consultant for Google on epigenetics and AI in healthcare, and a lecturer at Stanford University.
Brian Rose is the founder of London Real, a curator of people worth watching. Its mission is to promote personal transformation through inspiration, self-discovery and empowerment.
CUENTA CON SUBTÍTULOS EN ESPAÑOL
To watch the entire conversation clic here: https://youtu.be/ynbaJ2038K0

Could speed up healing.


Wound healing in mammalian skin often results in fibrotic scars, and the mechanisms by which original nonfibrotic tissue architecture can be restored are not well understood. Here, Wei et al. have shown that pharmacological activation of the nociceptor TRPA1, which is found on cutaneous sensory neurons, can limit scar formation and promote tissue regeneration. They confirmed the efficacy of TRPA1 activation in three different skin wounding mouse models, and they also observed that localized activation could generate a response at distal wound sites. TRPA1 activation induced IL-23 production by dermal dendritic cells, which activated IL-17–producing γδ T cells and promoted tissue regeneration. These findings provide insight into neuroimmune signaling pathways in the skin that are critical to mammalian tissue regeneration.

Adult mammalian wounds, with rare exception, heal with fibrotic scars that severely disrupt tissue architecture and function. Regenerative medicine seeks methods to avoid scar formation and restore the original tissue structures. We show in three adult mouse models that pharmacologic activation of the nociceptor TRPA1 on cutaneous sensory neurons reduces scar formation and can also promote tissue regeneration. Local activation of TRPA1 induces tissue regeneration on distant untreated areas of injury, demonstrating a systemic effect. Activated TRPA1 stimulates local production of interleukin-23 (IL-23) by dermal dendritic cells, leading to activation of circulating dermal IL-17–producing γδ T cells. Genetic ablation of TRPA1, IL-23, dermal dendritic cells, or γδ T cells prevents TRPA1-mediated tissue regeneration.